Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Search

Astellas Pharma Inc.

Japan
  • About
    • President and CEO’s Message
    • Philosophy
      • Charter of Corporate Conduct
    • Vision & Strategy
    • Corporate Governance
      • Group Code of Conduct
    • Risk Management
    • Corporate Information
      • Subsidiaries & Locations
      • Management
    • History
    • Board of Directors
    • Top Management
    • Main Products
    • Policies & Position Statements
    • Ethics & Compliance
    • Medical Care & Pharmaceutical Information
    Recommended
    Strategic Plan 2018
    Read More
  • Science
    • Focus Area Approach
    • Astellas Biomedical Innovation Hub
    • Rx+®
    • Data, Informatics and Analytics
    • Major Pipeline
    • Clinical Trials
    Recommended
    Focus Area Approach

    The Focus Area, where we put our efforts, consists of combinations of three components: 1) biology, 2) modality/technology, 3) diseases.

    Read More
  • Partnering
    • Areas of Interest
    • Why Partner with Astellas
    • Primary Focus
      • Blindness & Regeneration
      • Mitochondria Biology
      • Genetic Regulation
      • Immuno-Oncology
    • Biology, Modality/Technology of Interest
      • Innate Immunity (Innate Lymphoid Cells)
      • Autophagy
      • Protein Knockdown
    • Primary Focus Candidates
    • Cell Therapy
    • Rx+® - New Healthcare Solutions Beyond Medicine
      • Chronic Disease Progression Prevention
      • Motor Function Support/Replacement
      • Digital × Neuroscience
      • Patient w/o Effective Medicines
      • Patient Outcome Maximization via Precise Surgery/Diagnosis
      • Sensory Function Support/Replacement
    • Partnering Teams
    • Get in Touch
    • For Academics
    Recommended
    Areas of Interest

    Astellas monitors Focus Areas from biology perspectives, modality/technology, and disease to identify promising areas for investment. 

    Read More
  • Responsibility
    • Our Commitment
    • Our CSR-Based Management
      • Materiality in CSR Activities
      • SDGs
      • ISO26000 and CSR-Based Management
      • United Nations Global Compact
      • 30% Club
    • Access to Health
      • Research Activities on Tuberculosis and Malaria
      • Research Activities on NTDs
      • Development of Pediatric Formulation for Schistosomiasis
      • GHIT Fund
      • Access Accelerated
      • Action on Fistula
    • Stakeholder Communications
      • Peer Support Training Program (in Japan)
      • Communication with Patients (in U.S.)
      • Communication with the World Anti-Doping Agency (WADA)
      • Local Community Dialogue
    • Five Fields of CSR-Based Management
      • Five Fields of CSR-Based Management Diagram
    • Business Activities
      • Responsible Business Activities
      • With our Business Partners
        • Basic policy for procurement activities involving suppliers
      • Modern Slavery Act 2015
      • Individual HCP Funding Decision
    • Society
      • Priority Areas of Astellas Domestic Social Contribution Activities
      • 1st priority
      • 2nd priority
      • 3rd priority
        • Changing Tomorrow Day
        • Flying Star Fund (Japan)
        • Donation of wheelchair vans in Japan
        • Donation of Ambulances in Japan
        • Disaster Relief Activities
      • Astellas Foundation
    • Environment
      • Definition of terms
      • EHS Management
        • Status of obtaining ISO Certification
        • Astellas Environment, Health & Safety Guidelines
      • Environment Initiatives
      • Climate Change Mitigation Measures
      • Breakdown of Energy Consumption
      • Sustainable Biodiversity Initiatives
        • Biodiversity and Astellas An Enlarged Version
        • The Biodiversity Burden Index and Revenue
      • Initiatives for Resource Recycling
      • Initiatives for Preventing Pollution
        • Further information on PRTR system
      • Environmental Impact of Products and Countermeasures
      • Environmental Accounting
        • Environment-related Investments and Expenses
      • Reporting coverage, methods, etc.
      • EHS Report
      • Independent Assurance Report
    • EMPLOYEES
      • HR Vision
      • Providing Opportunities for Employees to Succeed Globally
      • Diversity Management
      • Promoting Health Management
      • Occupational Health & Safety
      • Respect for Human Rights
      • Data
        • Major Programs (Japan)
        • Major Data (Japan)
    • Ethics & Compliance
    Recommended
    Access Accelerated

    Astellas participates in Access Accelerated. Access Accelerated is a first-of-its-kind, multi-stakeholder collaboration focused on improving...

    Read More
  • News
    • News
    • Stories
    Recommended
    Stories

    Stories about how Astellas members work to create innovation, as well as achieve business and sustainability strategic goals.

    Read More

Stakeholders menu

  • Investors
    • Strategic Plan 2018
    • Financial Information
      • Financial Highlights
      • Financial Data (Annual Data)
      • Financial Data (Quarterly Data)
      • Sales of Major Products
      • Revenue by Region
    • Annual Report
    • IR Library
      • Business Results
      • Overview of R&D Pipeline
      • IR Meetings
      • Consolidated Financial Statements and Footnotes
      • Corporate Governance Materials
    • IR Calendar
    • Stock & Rating Information
      • Shareholders Meeting
      • Shareholder Return
      • Current Share Status
      • Chart
      • Ratings
    • Analyst Coverage
    • Cautionary Statement
  • Careers
  • Contact Us

Common header menu

  • IMPORTANT NOTICE
  • WORLDWIDE
  • 日本語
  • English
  1. Home
  2. Investors
Important Notice

This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.

Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.

I Agree
logo
Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.
(This link opens in a new window)
Cancel Click here to leave this site.

Investor Relations

Investors
Investors

Stock Quotes(TSE 1st:4503)

View Stock Performance

IR News

Jan 29, 2021
Posted Financial Results for 3Q/FY2020
Dec 10, 2020
Updated “R&D Meeting” Section
Oct 30, 2020
Posted Financial Results for 2Q/FY2020
Sep 30, 2020
Annual Report 2020 is now available.
Aug 04, 2020
Posted Financial Results for 1Q/FY2020
May 27, 2020
Posted Notice of Convocation of the 15th Term Annual Shareholders
View All >>
Strategic Plan 2018

Our Corporate Strategic Plan 2018 provides a path to realizing VISION in the coming years.

Read More
Financial Information

Review our consolidated business results, forecasts and financial data, etc.

Read More
Annual Report

Annual report site. CEO message, mid- and long-term strategy, corporate governance, business review, and financial information are summarized in this web site.

Read More
IR Library

This section contains IR related information for shareholders and investors. Various IR materials can be downloaded from here.

Read More
IR Calendar

Find our upcoming IR events.

Read More
Stock & Rating Information

Year-end dividend - March 31 Interim dividend - September 30 Note: In accordance with the Company's Articles of Incorporation, if cash dividends are not claimed for three (3) full years from the day of commencement of payment, the Company shall be relieved of the obligation to make such payment.

Read More
Analyst Coverage

List of analysts of securities companies and research companies who make recommendations and reports of Astellas' performance, etc

Read More
Cautionary Statement

The information disclosed in this part of the Astellas Website is provided for better understanding of Astellas by stakeholders including shareholders and investors, but is intended to neither solicit nor recommend the purchase of the Astellas's stock.

Read More
Strategic Plan 2018

 

 

Read More
Vision & Strategy

On the forefront of healthcare change to turn innovative science into value for patients.

Read More
Major Pipeline

We introduce the progress of our clinical development projects called "R&D pipeline". We update R&D pipeline 4 or 5 times annually in our quarterly performance reports.

Read More

Follow us on social media

Youtube Logo

Bottom footer menu

  • SITE MAP
  • PRIVACY POLICY
  • ACCESSIBILITY
  • TERMS OF USE
  • CONTACT US
  • DISASTER INFORMATION FOR EMPLOYEES
© Astellas Pharma Inc.